Key result
Ranolazine treatment for 3 months significantly reduced the mean number of angina episodes per week from 4.4 at baseline to 1.1 (p<0.0001).
Why the study?
Does ranolazine improve angina symptoms and quality of life in patients with stable angina pectoris?
Observational (n=2,726)
Does ranolazine improve angina symptoms and quality of life in patients with stable angina pectoris?
Absolute Event Rate: 1.1% vs 4.4%
p-value: p=<0.0001
In a real-world setting, adjuvant therapy with ranolazine significantly reduces angina episodes and short-acting nitrate use while improving quality of life in patients with stable angina pectoris.
Ranolazine may be safe and effective in real-world stable angina; leaves open randomized confirmation before practice change.
Objective: Ranolazine, a late sodium current inhibitor, is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antiischaemic therapies. This study was conducted to assess the use of ranolazine as well as its safety and efficacy in patients with stable angina pectoris from different causes in a real world scenario. Methods: Patients with stable angina pectoris (AP) receiving ranolazine were enrolled in this non-interventional study. Data were documented at baseline and after 3 months of ranolazine treatment. Endpoints included changes in the number of AP attacks per week, frequency of using short-acting nitrates, current status of the CCS classification, overall estimate of quality of life assessed by both, the physician and the patient, and safety. Results: In total, 1,537 patients were eligible for efficacy evaluation. After 3 months, the mean (±SD) number of AP episodes per week significantly decreased from 4.4 ± 4.0 at baseline to 1.1 ± 1.8 (p<0.0001), and the weekly use of short-acting nitrates was significantly reduced from 3.4 ± 3.4 to 0.8 ± 1.5 (p<0.0001). Improvement occurred independent of diagnosed coronary heart disease (CHD). The CCS classification improved in 69.0% of patients and remained stable in 27.1%. Quality of life, assessed on a numerical analogue scale by physicians and patients, improved significantly by 43.7% and 44.9%, respectively (p<0.0001). Safety analysis was based on 2,726 patients. A total of 63 adverse drug reactions (ADRs) occurred in 37 patients (1.4%) and led to discontinuation in 34 patients (1.2%). By the end of the observation period, all ADRs were resolved or resolving. Conclusion: The adjuvant therapy with ranolazine is an effective treatment option with a positive benefit-risk balance for patients with angina pectoris of different causes, e.g. small vessel disease, endothelial dysfunction, including those without prior CHD diagnosis.
No takes yet. Share an insight, caveat, or question.
Diedrichs et al. (2015) conducted an observational in stable angina pectoris (n=2,726). Ranolazine vs. Baseline was evaluated on changes in the number of AP attacks per week (p=<0.0001). Ranolazine treatment for 3 months significantly reduced the mean number of angina episodes per week from 4.4 at baseline to 1.1 (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: